Quince therapeutics inc QNCX.US Overview Analysis
QNCX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
QNCX Current Performance
-3.67%
Quince therapeutics inc
-3.92%
Avg of Sector
-0.77%
S&P500
Top 10 High Relevance to QNCX
- EPRX Eupraxia pharmaceuticals incValue -Trend 4Swing Trading 2Whale Interest -Dividend 1See more
QNCX Profile
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient's own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. The Company's Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.